Cancer Clinical Trial Matching - DrArturoAI-AI-powered cancer trial matching

Example

For a patient with metastatic melanoma who has already tried immune checkpoint inhibitors like pembrolizumab, DrArturoAI would avoid trials using similar immune checkpoint therapies. Instead, it would focus on those utilizing novel mechanisms of action such as oncolytic viruses or T-cell therapies.

Scenario

A patient with advanced-stage cancer is looking for options after standard treatments have failed. By inputting their treatment history, biomarker profile (e.g., PD-L1 expression, BRAF mutations), and current cancer stage, the platform filters out trials with previously ineffective treatments, narrowing down trials that align with new, experimental therapies suited to their condition.

Example

A patient with HER2-positive breast cancer seeking a second-line treatment would have trials filtered based on the HER2 biomarker. DrArturoAI prioritizes trials utilizing HER2-targeted therapies like trastuzumab derivatives or newer monoclonal antibodies.

Scenario

For patients with distinct genetic alterations (e.g., HER2, EGFR, ALK), DrArturoAI identifies clinical trials focused on these genetic targets, excluding trials irrelevant to their biomarker profile. This can be particularly useful for rare or hard-to-treat cancers where genetic mutations play a crucial role in determining effective treatments.

Example

If a patient with colorectal cancer has undergone FOLFOX (a chemotherapy regimen), DrArturoAI ensures that trials involving oxaliplatin-based regimens are excluded to prevent redundancy and avoid ineffective or harmful treatments.

Scenario

A colorectal cancer patient who has already shown progression on FOLFOX is searching for clinical trials. The AI excludes any trial with oxaliplatin (part of the FOLFOX regimen), instead surfacing options like trials with immune checkpoint inhibitors, cellular therapies, or combinations targeting KRAS mutations.